# A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)

> **NCT04428281** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 74 (actual)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** RO7248824

## Key facts

- **NCT ID:** NCT04428281
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428281, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04428281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*